-
Pharma News Review of PharmaSources (February) - Business
Industry Data
Caicai/PharmaSourcesMarch 14, 2023
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
-
Monthly Pharma News Review of PharmaSources (February) - Chinese Drug review and approval
Industry Data
Caicai/PharmaSourcesMarch 14, 2023
The anti-PD-L1 monoclonal antibody Adebrelimab from Hengrui Pharmaceuticals was approved for marketing, and the Class 3 chemotherapy Limaprost tablets from Sino Biopharm were approved for marketing.
-
Monthly News Review of PharmaSources (February) - R&D
Industry Data
Caicai/PharmaSourcesMarch 13, 2023
In R&D, Chipscreen chidamide Ⅲ test reaches preset indicators, the company plans to submit an application for the marketing of a new indication.
-
The Accepted Marketing Application of Roche's Glofitamab in China
Industry Data
Yefenghong/PharmaSourcesMarch 01, 2023
Recently, the marketing application of Roche's Glofitamab has been accepted by NMPA in China.
-
The R&D of CD20/CD3 Bispecific Antibody in China
Industry Data
Yefenghong/PharmaSourcesMarch 01, 2023
Currently, the R&D of CD20/CD3 bispecific antibody is still in the early stage. In China, few CD20/CD3 bispecific antibodies have entered the clinical stage, among which GB261 from Genor Biopharma has a good progress.
-
The Performance of the Two Insulin Companies on Volumn-based Procurement in the First Year
Industry Data
Yefenghong/PharmaSourcesMarch 01, 2023
Two leaders of insulin made in China, Tonghua Dongbao and Gan & Lee Pharmaceuticals, has announced their performance in 2022 respectively. As the first year of centralized procurement of insulin, two companies' performance both declined in 2022.
-
The Coming Successor and the Ending Humira
Industry Data
Yi/PharmaSourcesMarch 01, 2023
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
-
First Generic Drugs Approved in China in 2022
Industry Data
Zhulikou/PharmaSourcesFebruary 15, 2023
List of the First Generic Drugs Approved in China in 2022
-
Weekly Pharma News Review | PharmaSources.com （Feb.6th - 10th, 2023）
Industry Data
CaicaiFebruary 13, 2023
A new indication of Pfizer's tofacitinib sustained release tablet was approved in China; Phase III study of obesity indication of Eli Lilly's Tirzepatide succeeded in China.
-
A Glimpse of the Capacity and Supply of Blood Products Made in China
Industry Data
XiaoyaowanFebruary 08, 2023
Gamma globulin is the passive immunity preparation, of which the most widely used product in the clinical practice is the human immunoglobulin for intravenous injection, referred to PH4.
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
The anti-PD-L1 monoclonal antibody Adebrelimab from Hengrui Pharmaceuticals was approved for marketing, and the Class 3 chemotherapy Limaprost tablets from Sino Biopharm were approved for marketing.
In R&D, Chipscreen chidamide Ⅲ test reaches preset indicators, the company plans to submit an application for the marketing of a new indication.
Recently, the marketing application of Roche's Glofitamab has been accepted by NMPA in China.
Currently, the R&D of CD20/CD3 bispecific antibody is still in the early stage. In China, few CD20/CD3 bispecific antibodies have entered the clinical stage, among which GB261 from Genor Biopharma has a good progress.
Two leaders of insulin made in China, Tonghua Dongbao and Gan & Lee Pharmaceuticals, has announced their performance in 2022 respectively. As the first year of centralized procurement of insulin, two companies' performance both declined in 2022.
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
List of the First Generic Drugs Approved in China in 2022
A new indication of Pfizer's tofacitinib sustained release tablet was approved in China; Phase III study of obesity indication of Eli Lilly's Tirzepatide succeeded in China.
Gamma globulin is the passive immunity preparation, of which the most widely used product in the clinical practice is the human immunoglobulin for intravenous injection, referred to PH4.
Pharma Sources Insight JUNE2022
